Sanofi’s Lunsekimig Shows Promise in Respiratory Trials, Falls Short in Dermatitis

Sanofi is advancing lunsekimig through late-stage development, including two Phase III trials in Chronic Obstructive Pulmonary Disease (COPD). The drug has delivered positive Phase II results in respiratory conditions but showed limited efficacy in Atopic Dermatitis.

In asthma and chronic rhinosinusitis with nasal polyps, lunsekimig improved lung function and met primary endpoints. The AIRCULES Phase IIb asthma trial demonstrated reduced exacerbations and better lung performance, while the DUET Phase IIa study achieved significant improvements in nasal polyp and congestion scores.

However, the VELVET Phase IIb trial in dermatitis did not meet its main endpoint, despite some gains in secondary skin clearance measures. Lunsekimig, a bispecific Nanobody targeting TSLP and IL-13, was generally well tolerated.

The therapy is part of Sanofi’s pipeline aimed at succeeding Dupixent, amid strong competition in inflammatory disease treatments.

07-04-2026